NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB
Post# of 48
(Total Views: 162)
Posted On: 04/25/2024 4:15:49 PM
NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise
Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids. The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with the aim of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia. As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Nutriband.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids. The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with the aim of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia. As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Nutriband.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)